Roche Achieves Phase III Superiority for Divarasib Against Approved KRAS G12C Inhibitors in NSCLC

Regulatory submissions to FDA and EMA are the immediate next step after Roche reported that divarasib outperformed approved first-generation KRAS G12C inhibitors on both progression-free survival and overall survival in the phase III Krascendo 1 study, a result that carries direct CMC and manufacturing readiness implications for a molecule now positioned as a potential standard of care in previously treated KRAS G12C-mutant NSCLC.

The randomised, open-label, multicentre trial enrolled 338 adults and compared divarasib monotherapy against sotorasib or adagrasib. The study met its primary endpoint of blinded independent central review (BICR)-assessed progression-free survival and its key secondary endpoint of overall survival, with statistical significance achieved at the interim OS analysis. No new safety signals were detected; the most common treatment-related events were characterised as manageable and reversible, consistent with the existing divarasib safety dataset.

The KRAS G12C mutation is present in approximately 14% of NSCLC cases and carries a poor prognosis, making it a clinically significant genotype for oncology drug development. Divarasib holds Breakthrough Therapy Designation granted by the FDA in 2022 and received Orphan Drug Designation for KRAS G12C NSCLC in 2026. For QA directors and regulatory affairs leads, those designations compress standard review timelines and elevate the scrutiny applied to CMC packages, process validation data, and post-approval change management protocols during the submission window.

Roche's broader Krascendo programme extends divarasib evaluation into earlier lines of therapy and chemotherapy-free combination regimens, meaning manufacturing scale and supply-chain continuity planning will need to account for multiple concurrent indications. The Krascendo 1 dataset is described as the only global head-to-head comparison of a KRAS G12C inhibitor against approved agents in this setting, which strengthens the evidentiary basis for a priority review request but also raises the bar for the analytical comparability and stability data that health authorities will expect in the dossier.

Full data from Krascendo 1 are scheduled for presentation at an upcoming medical meeting ahead of formal submission to health authorities, with the interim OS readout serving as the pivotal anchor for the regulatory package.

Source: Roche via GlobeNewswire, 2 July 2026.